More EU competition looms for Plavix
This article was originally published in Scrip
Sanofi-Aventis is facing yet more competition for its blockbuster antithrombotic Plavix (clopidogrel) after the European Medicines Agency gave the green light to several more generic versions.
You may also be interested in...
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.
Stemline Therapeutics’ Elzonris was approved for a rare cancer in Europe in January, following a long and arduous two-year journey through the EU regulatory process that included an initial rejection and a subsequent re-examination by the EMA. Its fortunes were very different in the US, where the review took just six months from filing to approval.
Proposals for establishing a ‘European Health Union’ include measures to give the EU regulator more say in monitoring and mitigating potential and actual shortages of drugs and devices in the event of serious public health crises.